Comparative Study Evaluating Clinical Outcomes for Patients Treated With Tocilizumab for Sever COVID-19 Infection in Breast Cancer Patients Versus Non Cancer Patients
Latest Information Update: 04 Nov 2022
At a glance
- Drugs Tocilizumab (Primary)
- Indications Breast cancer; COVID 2019 infections
- Focus Therapeutic Use
- 31 Oct 2022 Status changed from recruiting to completed.
- 29 Sep 2021 Planned End Date changed from 26 Oct 2021 to 26 Aug 2022.
- 29 Sep 2021 Planned primary completion date changed from 26 Jul 2021 to 26 Jul 2022.